Outcomes in Hospitalized Patients With Subclinical Hypothyroidism

Area of Science:

• Cardiology
• Endocrinology
• Internal Medicine

Background:

• Subclinical hypothyroidism (SCH) is a condition characterized by elevated thyroid-stimulating hormone (TSH) with normal free thyroxine (T4) levels.
• The clinical significance of SCH in hospitalized patients, particularly regarding cardiovascular outcomes, remains unclear.

Purpose of the Study:

• To investigate the association between SCH and major adverse cardiovascular events (MACE) in hospitalized patients.
• To explore the relationship between SCH and in-hospital mortality, length of stay (LOS), and 30-day readmission rates.

Main Methods:

• Retrospective, multi-center study design.
• Inclusion criteria: hospitalized patients with available TSH and T4 levels.
• Exclusion criteria: abnormal free T4, history of thyroid disease, or thyroid medication use.

Main Results:

• 13.4% of euthyroid patients experienced MACE versus 14.2% in the SCH group.
• SCH group showed slightly higher mortality (5.9% vs 3.8%), 30-day readmission (23.2% vs 20.3%), and average LOS (4.89 vs 4.80 days).
• Logistic regression analysis revealed no statistically significant differences in MACE or secondary outcomes between groups.

Conclusions:

• While trends suggested increased MACE, mortality, readmission, and LOS in SCH patients, these differences were not statistically significant.
• Further prospective research is warranted to clarify the clinical implications of SCH in hospitalized populations.
• Refining management and treatment strategies for SCH requires additional evidence from well-designed studies.